Novartis and L'Oréal Deepen Cross-Industry Collaboration to Advance Dermatological Health

SingaporeJuly 6, 2023/PR Newswire/ -- The 25th World Congress of Dermatology (WCD2023) was held in Singapore from July 3-8, 2023. With the theme "Dermatology Beyond Borders," WCD2023 aimed to strengthen cross-regional cooperation. Attending clinicians, researchers, industry players, and other partners jointly committed to expanding the boundaries of dermatology to promote its development and improve public skin health.

In alignment with the WCD2023 theme, during the conference, Novartis China and L'Oréal announced a further deepening of their cross-sector collaboration to expand their "Integrated Treatment and Care" public welfare cooperation in the field of dermatological science. Attendees at this launch ceremony included Stiefel Timothy, Executive Director of Novartis’ Global Immunotherapy Division; Ms. Tian Yu, Head of the Immunotherapy Division at Novartis Innovative Medicines China; Ms. Melanie VIDAL, International Brand Director of CeraVe; Ms. Ma Lan, Vice President of L'Oréal China and General Manager of its Dermatological Beauty Division; and Ms. Zhou Shuangwei, General Manager of CeraVe China.

This cooperationBoth parties will continue to expand the dimensions of cooperation and deepen the intensity of collaboration, while continuously increasing support for public welfare projects involving tripartite health consultations. Efforts will be further extended to grassroots levels to raise public awareness on skin health and promote the scientific skincare concept of "integrating treatment with care." This initiative aims to provide more timely and scientific skincare guidance and standardized treatment for a large population with impaired skin barriers in China’s county-level regions, especially for patients suffering from skin diseases. Ultimately, this will help advance the healthy development of dermatological medicine in China, benefiting tens of thousands of psoriasis patients.

Ms. Melanie VIDAL, International Brand Director of CeraVe

Ms. Ma Lan, Vice President of L'Oréal China and General Manager of the Dermatological Beauty Division, stated: "With the mission of ‘Specialized Repair, Jointly Defending a Healthy Skin Barrier,’ we look forward to the planned joint dermatological research with our partners, which will help more patients reduce skin problems and improve their quality of life by establishing a healthy skin barrier. In the future, we will continue to focus on providing scientific skincare solutions for numerous skin barrier-related conditions, including psoriasis, and work together with partners from all sectors to advance the development of dermatological medicine, jointly painting a blueprint for ‘Beautiful Global Health.’"

Mr. Stiefel Timothy, Executive Director of Global Immunotherapy at Novartis

"Novartis has been deeply involved in the field of immunology for nearly 20 years, not only bringing several approved innovative drugs to patients, but also currently conducting hundreds of clinical trials for different indications," said Mr. Stiefel Timothy, Executive Director of Global Immunotherapy at Novartis.^[1]Notably, the fully human innovative biologic Secukinumab has brought comprehensive benefits to a cumulative total of one million psoriasis patients globally.^[2], quickly, effectively, and durably alleviating disease symptoms, thereby significantly helping to improve patients' quality of life and happiness index.^[3]"In the future, we will also join hands with all partners to continue our journey together, helping more patients gain a new life."

Ms. Tian Yu, Head of Immunotherapy at Novartis Innovative Medicines China

Tian Yu, Head of Immunology at Novartis Innovative Medicines China, expressed high recognition for the collaboration between both parties: "Novartis China has always been committed to advancing the fields of dermatology and rheumatology. Our innovative drugs in the immunotherapy sector have benefited more than 350,000 Chinese patients with psoriasis, urticaria, and ankylosing spondylitis. The series of cross-sector collaborations between Novartis and L'Oréal's Dermatological Beauty Division not only mark a breakthrough milestone in industry cooperation but also serve as a successful example of public welfare collaboration that integrates treatment and care within the field of dermatological science."

"This year, we will continue to focus on patients' skin health, and work with L'Oréal to bring more skin care programs and scientific treatment education to patients suffering from skin diseases, contributing to Healthy China 2030.""。Ms. Tian Yu stated.

Melanie VIDAL, International Brand Director of CeraVe

Melanie VIDAL, International Brand Director of CeraVe, stated: "Globally, CeraVe, a brand under L'Oréal Group, has always been committed to the core mission of skin barrier repair, aiming to further drive innovation in the field of scientific dermatological beauty. With professional and scientific skincare solutions, we lead the way in promoting healthy beauty. Therefore, we are collaborating with partners from various professional backgrounds in the greater health industry to deepen the integration of the beauty and wellness ecosystem, helping more people overcome skin issues and scientifically enjoy a beautiful life."

In addition, the two parties will continue to deepen cooperation in the future, promoting research and exploration into clinical issues in the field of psoriasis, with broader and deeper coverage. Psoriasis is a chronic inflammatory skin disease caused by the interaction of epidermal keratinocytes and immune cells, and its pathogenesis is still unclear. However, an increasing number of studies indicate that abnormalities in skin barrier function are closely related to the onset of psoriasis and may be one of the main triggers of the disease.^[4]Patients suffering from psoriasis usually experience various skin problems such as itching, scaling, dryness, and lesions, which bring a significant burden to their physical and mental health. Novartis and L'Oréal are jointly committed to bringing better quality of life and infinite future possibilities to patients with psoriasis.

[1] Search results for ongoing/completed clinical trials with secukinumab on clinicaltrials.gov

[2] Novartis data on file. Cosentyx cumulative patients served. January 2023.

[3] The Complete Cosentyx Approach is defined as efficacy in both skin and persistent psoriasis manifestations in nails, scalp, palms, and soles, as well as psoriatic arthritis; controls irreversible structural damage (psoriatic arthritis) and improves quality of life.

[4] Ye Li, Maoqiang Man, Chengzhi Lü. Abnormal Skin Barrier Function and Psoriasis[J]. Dermatological Science Bulletin, 2017,34(4):6.DOI:CNKI:SUN:ZYXW.0.2017-04-013.